Page 35 - Vitamin D and Cancer

22 H.S. Cross

75. Soronen P, Laiti M, Torn S et al (2004) Sex steroid hormone metabolism and prostate cancer.
J Steroid Biochem Mol Biol 92(4):281–286
76. Wang JH, Tuohimaa P (2007) Regulation of 17beta-hydroxysteroid dehydrogenase type 2,
type 4 and type 5 by calcitriol, LXR agonist and 5alpha-dihydrotestosterone in human pros-
tate cancer cells. J Steroid Biochem Mol Biol 107(1–2):100–105
77. Lou YR, Murtola T, Tuohimaa P (2005) Regulation of aromatase and 5alpha-reductase by
25-hydroxyvitamin D(3), 1alpha, 25-dihydroxyvitamin D(3), dexamethasone and progester-
one in prostate cancer cells. J Steroid Biochem Mol Biol 94(1–3):151–157
78. Kaeding J, Belanger J, Caron P, Verreault M, Belanger A, Barbier O (2008) Calcitrol
(1alpha, 25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer
cells. Mol Cancer Ther 7(2):380–390
79. Zhao XY, Ly LH, Peehl DM, Feldman D (1999) Induction of androgen receptor by 1alpha,
25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
Endocrinology 140(3):1205–1212
80. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D, Peehl DM (2004) Mechanisms of
decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol Cell
Endocrinol 221(1–2):67–74
81. Wu S, Ren S, Nguyen L, Adams JS, Hewison M (2007) Splice variants of the CYP27b1 gene and
the regulation of 1, 25-dihydroxyvitamin D3 production. Endocrinology 148(7):3410–3418
82. Diesel B, Radermacher J, Bureik M et al (2005) Vitamin D(3) metabolism in human glio-
blastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol,
and effect of calcitriol. Clin Cancer Res 11(15):5370–5380
83. Maas RM, Reus K, Diesel B et al (2001) Amplification and expression of splice variants of
the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1, alpha-hydroxylase
(CYP 27B1) in human malignant glioma. Clin Cancer Res 7(4):868–875
84. Radermacher J, Diesel B, Seifert M et al (2006) Expression analysis of CYP27B1 in tumor
biopsies and cell cultures. Anticancer Res 26(4A):2683–2686
85. Fischer D, Seifert M, Becker S et al (2007) 25-Hydroxyvitamin D3 1alpha-hydroxylase
splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genom Proteom
4(4):295–300
86. Ren S, Nguyen L, Wu S, Encinas C, Adams JS, Hewison M (2005) Alternative splicing of
vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1, 25-dihy-
droxyvitamin D synthesis. J Biol Chem 280(21):20604–20611
87. Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL (2007) CYP24 splic-
ing variants are associated with different patterns of constitutive and calcitriol-inducible
CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol
103(3–5):334–337
88. Slattery ML, Wolff RK, Curtin K et al (2009) Colon tumor mutations and epigenetic changes
associated with genetic polymorphism: Insight into disease pathways. Mutat Res
660(1–2):12–21
89. Hawkins GA, Cramer SD, Zheng SL et al (2002) Sequence variants in the human 25-hy-
droxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate
cancer risk. Prostate 53(3):175–178
90. Roff A, Wilson RT (2008) A novel SNP in a vitamin D response element of the CYP24A1
promoter reduces protein binding, transactivation, and gene expression. J Steroid Biochem
Mol Biol 112(1–3):47–54
91. Barault L, Charon-Barra C, Jooste V et al (2008) Hypermethylator phenotype in sporadic colon
cancer: study on a population-based series of 582 cases. Cancer Res 68(20):8541–8546
92. Kim MS, Fujiki R, Kitagawa H, Kato S (2007) 1alpha, 25(OH)2D3-induced DNA methyla-
tion suppresses the human CYP27B1 gene. Mol Cell Endocrinol 265–266:168–173
93. Chung I, Karpf AR, Muindi JR et al (2007) Epigenetic silencing of CYP24 in tumor-derived
endothelial cells contributes to selective growth inhibition by calcitriol. J Biol Chem
282(12):8704–8714